Orthopediatrics Corp Raises Outlook Amid EBITDA Turnaround

Orthopediatrics Corp ((KIDS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Orthopediatrics Corp’s latest earnings call struck an optimistic tone, with management emphasizing accelerating growth, improving margins and a return to positive adjusted EBITDA. While acknowledging lingering losses, higher operating expenses and some timing risks, executives highlighted record patient impact, robust product momentum and raised guidance as evidence that the company’s pediatric orthopedics strategy is gaining traction.

Record Patient Reach Reinforces Mission and Market Relevance

Orthopediatrics reported supporting treatment for a record 45,000 children in the first quarter, underscoring the company’s expanding clinical footprint in pediatric orthopedics. Cumulatively, the firm has now helped nearly 1.4 million patients, a milestone management framed as both proof of mission-driven impact and validation of its long-term market opportunity.

Double-Digit Revenue Growth Driven by U.S. and International Strength

First-quarter 2026 revenue rose 13% year over year to $59.4 million, reflecting healthy momentum across the portfolio. U.S. sales climbed 11% to $45.3 million and represented 76% of the total, while international revenue grew roughly 22% to about $14.1 million, lifting its contribution to approximately 24% of company-wide sales.

Raised Full-Year Outlook Signals Confidence in Growth Trajectory

Management increased full-year 2026 revenue guidance to a range of $263 million to $267 million, implying 11% to 13% growth and signaling confidence in sustained demand. The company also reaffirmed its targets of about $25 million in adjusted EBITDA, roughly $10 million of set deployments and achieving full-year free cash flow breakeven in 2026.

Adjusted EBITDA Swings to a Positive Result

The company delivered adjusted EBITDA of $2.2 million in the quarter, a sharp improvement from an adjusted EBITDA loss of $0.4 million a year earlier. Management highlighted this as evidence of increasing operating leverage, with higher revenue beginning to outpace the growth in expenses as new products scale through the system.

Profitability and Liquidity Metrics Show Gradual Progress

Free cash flow usage improved to $5.0 million, a roughly 40% better result than the $8.4 million outflow in the prior-year quarter. The company ended Q1 with $50.9 million in cash, short-term investments and restricted cash and also added a $20 million delayed-draw term loan facility, bolstering liquidity as it invests in growth initiatives.

New Product Super Cycle Fuels Launch Momentum

Orthopediatrics cited strong early beta performance from its 3P Hip and Vertiglyde systems, noting robust demand and encouraging feedback from surgeons. Additional pipeline milestones include the 3P Small Mini beta launch scheduled for late second quarter and first-in-patient procedures for Veraxis and Ellie by year-end, with management expecting higher selling prices and margin expansion from this wave of innovation.

Specialty Bracing Delivers 20% Plus Growth and Footprint Expansion

The company’s specialty bracing segment, OPSB, posted over 20% growth in the quarter, supported by healthy same-store sales and new clinic openings. Management said it is ahead of plan on its clinic build-out and remains on track toward operating 27 territories by 2027, using a mix of greenfield locations and selective acqui-hires.

EU MDR Approvals Unlock European Growth in Second Half

Orthopediatrics secured full EU MDR approval for its trauma and deformity, scoliosis and external fixation portfolios, a key regulatory hurdle for continued European commercialization. Management expects these approvals to support stronger EMEA growth in the back half of 2026 as it ramps sets and logistics to better serve surgeons across the region.

Scoliosis Franchise Gains from Vertiglyde and 7D Technology

Scoliosis revenue reached $15.4 million, up 13% versus the prior year, reflecting solid uptake of the Response and Vertiglyde systems alongside continued integration of the 7D technology platform. Around 80 surgeons have now been trained on Vertiglyde, and management plans a full market release in the second quarter, citing demand as a key driver of future franchise growth.

Digital, Robotics and AI Investments Target Efficiency Gains

On the technology front, the company has launched beta deployments of Playbook, a digital workflow tool aimed at streamlining procedures and data capture. It also completed the first pediatric cases using the Iota Motion robot and is pushing forward with AI projects, with a goal of deploying six to eight targeted AI agents to improve both clinical and operational efficiency.

Weather Disruptions Temporarily Shifted Demand into Q2

Management noted that severe winter weather led to temporary shutdowns at OPS clinics in January and February, softening the start to the quarter. Many of those appointments were rescheduled into March and April, effectively shifting some activity from Q1 into Q2 and modestly muting reported first-quarter results despite underlying demand remaining intact.

Net Losses Persist Despite Operating Improvements

Even with better margins, Orthopediatrics remains unprofitable on a per-share basis, reporting a GAAP net loss per share of $0.45 compared with $0.46 in the prior year. Non-GAAP net loss per share widened slightly to $0.42 from $0.39, reminding investors that the path to sustainable profitability still requires continued growth and cost discipline.

Higher Operating Expenses Raise Sensitivity to Growth Pace

Total operating expenses rose 5% year over year to $51.7 million, including an 11% increase in sales and marketing costs to $18.5 million driven by higher commissions and unit volumes. General and administrative expenses also climbed 2% to $31.0 million, a larger cost base that could pressure margins if revenue growth slows or new product adoption lags expectations.

Lower Set Deployment Strategy Balances Capital and Growth

Set deployments in the quarter fell to $2.3 million from $3.6 million a year ago, a roughly 36% decline that management described as intentional. The company argued that newer, higher-priced systems can drive more revenue per dollar of set capital, though the lower deployment level could temporarily temper the pace at which implant revenue is recognized.

Free Cash Flow Still Negative Amid Transition

Although significantly improved, free cash flow remained negative at $5.0 million for the quarter, reflecting ongoing investments in growth and infrastructure. Management cautioned that quarterly cash flow will likely be uneven, with some periods positive and others negative, even as it reiterates a goal of breakeven for the full year.

Execution and Timing Risks Temper the Bull Case

Executives acknowledged that several growth levers rely on timely set availability, regulatory processes and scaling new product launches across geographies. They cautioned that delays in European logistics, 3P set supply or the rollout of platforms such as Veraxis and Ellie could act as rate limiters on revenue realization, making execution a key focus for investors.

Guidance Underscores Optimism on Growth, Margins and Cash

Reiterating confidence in its strategy, Orthopediatrics raised its 2026 revenue outlook to $263 million to $267 million while pointing to Q1 results as proof points for the trajectory. Management’s guidance rests on continued market share gains, sustained 20% plus OPSB growth, international acceleration and a multiyear product cycle that it believes will lift average selling prices, margins and overall capital efficiency.

Orthopediatrics’ latest earnings call painted the picture of a company in the midst of a profitable growth transition, with double-digit revenue gains and positive adjusted EBITDA offset by continued net losses and elevated costs. For investors, the key watch points will be execution on the ambitious product and geographic expansion plans, as well as the company’s ability to hit its cash flow and profitability milestones over the next several quarters.